Vaccine hope, Biden and central bank policy: The outlook for multi-asset in 2021

Sunil Krishnan highlights some of the themes that will shape multi-asset investing in 2021.

Vaccine hope, Biden and central bank policy: The outlook for multi-asset in 2021

1. Better than expected progress on COVID-19 vaccines is consequential, not necessarily in the next three to six months but longer term. It allows investors and companies to see light at the end of the tunnel and feeds into expectations of a recovery in 2021.

The efficacy of the Pfizer and Moderna vaccines is higher than anticipated, which should reduce the number of infections among recipients and accelerate herd immunity, speeding up the recovery. Having more than one drug with a high efficacy rate is another positive surprise.

Companies thinking about investments for the medium term can have more confidence in the state of global demand for 2022 and beyond

This feeds into upgraded expectations for an economic revival. Households may feel more confident spending additional savings built up during the pandemic. On the corporate side, even if there is a difficult period ahead, companies thinking about investments for the medium term can have more confidence in the state of global demand for 2022 and beyond.

For governments, it will be easier to frontload fiscal support to bridge the difficult winter period, as the same scale of emergency measures is unlikely to be needed next year. That will multiply the support fiscal policy can provide if governments have the will – though there may be obstacles if power is shared between the parties in the US, or as philosophical differences emerge among Conservatives in the UK.

Still, this overall picture is supportive for risk assets generally, across a range of companies, regions and industries. We do expect volatility, from near-term news on other vaccines, positive or negative, but also from the current period of pandemic management we have to get through. Restrictions are probably at their peak in Europe but are likely on the way up in the US, which will draw attention.

2. A divided US administration makes significant fiscal measures less likely. While a Biden government will take a more measured approach to China, we expect continued friction as both countries work to establish distinct spheres of influence.

With the US Senate currently expected to remain in Republican hands, we are unlikely to see a strong spirit of cooperation in Washington, reining in investor expectations for new pandemic support measures and any large-scale tax reform.

The decoupling between the US and China is unlikely to reverse materially

Internationally, the US may take a more measured approach than in the Trump years, but the decoupling between the US and China is unlikely to reverse materially. The rivalry will grind on as both countries establish their spheres of influence, at times creating uncertainty for investors.

While this will be slow moving, it will gradually provide more diversification between emerging and developed markets. A greater share of emerging markets will be driven by an independent Chinese economic pole and demand there, as opposed to a proxy of US demand going through global trade. Investors need to start thinking about China as a genuinely independent economic engine.

3. Central banks have changed how they think about inflation. The question for 2021 is whether they can stick to their commitment to more reflationary policies in the face of a strong recovery, or if they are drawn back into economic orthodoxy.

The US Federal Reserve is not alone in rethinking its goals; but its 2020 framework review significantly changed how the bank defines and achieves price stability, for the first time targeting temporary overshoots of the two per cent inflation objective. This is a significant evolution with broad reflationary implications, which over time may lead to steeper yield curves and supportive conditions for risky assets like equities. Currency markets may also feel the ripples: central banks making the most radical changes will potentially drive their currencies lower, and the US review could fall into this category.

Can central banks stick to this commitment if unemployment rates come down?

A key question we expect an answer to in 2021 is whether central banks can stick to this commitment if unemployment rates come down, allowing economies to run a little hot before they consider tightening. They understand the issues of having undershot inflation targets so much in recent years, but if they do stick to their commitment it will be an important change for investors’ long-term investment strategies, not just their tactical positioning.

4. In the UK, monetary policy will likely ease further amid COVID and Brexit headwinds, limiting potential rises in Gilt yields and sterling. Later in the year, however, a weaker currency and the vaccine rollouts could benefit FTSE 100 companies.

Our central case is for a “skinny” Brexit deal to be agreed between the UK and EU before the end of 2020. However, this does not mean it is plain sailing for the UK. The combination of a winter of tough COVID restrictions, and major post-Brexit adjustments for several sectors, are likely to create headwinds for the economy early in 2021.

The result could be a revival for the UK’s largest companies

Monetary policy is likely to ease further, though the Bank of England’s Monetary Policy Committee appears split on whether further bond purchases will prove sufficient. The debate over negative interest rates is likely to remain live into the spring, limiting rises in Gilt yields. Against this backdrop, recent gains in sterling may also prove hard to sustain. This may, interestingly, provide some support for the FTSE 100, which tends to benefit from translating overseas earnings when the pound is weak. When coupled with inexpensive valuations after many years of lagging returns seen overseas, the result could be a revival for the UK’s largest companies. 

Looking further ahead, the UK could be a prime beneficiary of vaccine rollouts, given the high share of services spending in the economy and significant recent investment in vaccination infrastructure. It may be that the end of 2021 brings light at the end of the tunnel for the UK economy and currency.

Want more content like this?

Sign up to receive our AIQ thought leadership content.

Please enable javascript in your browser in order to see this content.

I acknowledge that I qualify as a professional client or institutional/qualified investor. By submitting these details, I confirm that I would like to receive thought leadership email updates from Aviva Investors, in addition to any other email subscription I may have with Aviva Investors. You can unsubscribe or tailor your email preferences at any time.

For more information, please visit our Privacy Policy.

Important information

Except where stated as otherwise, the source of all information is Aviva Investors Global Services Limited (AIGSL). Unless stated otherwise any views and opinions are those of Aviva Investors. They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Investors nor as advice of any nature. Information contained herein has been obtained from sources believed to be reliable but has not been independently verified by Aviva Investors and is not guaranteed to be accurate. Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. Nothing in this material, including any references to specific securities, assets classes and financial markets is intended to or should be construed as advice or recommendations of any nature. This material is not a recommendation to sell or purchase any investment.

In Europe this document is issued by Aviva Investors Luxembourg S.A. Registered Office: 2 rue du Fort Bourbon, 1st Floor, 1249 Luxembourg. Supervised by Commission de Surveillance du Secteur Financier. An Aviva company. In the UK Issued by Aviva Investors Global Services Limited. Registered in England No. 1151805. Registered Office: St Helens, 1 Undershaft, London EC3P 3DQ. Authorised and regulated by the Financial Conduct Authority. Firm Reference No. 119178. In France, Aviva Investors France is a portfolio management company approved by the French Authority “Autorité des Marchés Financiers”, under n° GP 97-114, a limited liability company with Board of Directors and Supervisory Board, having a share capital of 17 793 700 euros, whose registered office is located at 14 rue Roquépine, 75008 Paris and registered in the Paris Company Register under n° 335 133 229. In Switzerland, this document is issued by Aviva Investors Schweiz GmbH.

In Singapore, this material is being circulated by way of an arrangement with Aviva Investors Asia Pte. Limited (AIAPL) for distribution to institutional investors only. Please note that AIAPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIAPL in respect of any matters arising from, or in connection with, this material. AIAPL, a company incorporated under the laws of Singapore with registration number 200813519W, holds a valid Capital Markets Services Licence to carry out fund management activities issued under the Securities and Futures Act (Singapore Statute Cap. 289) and Asian Exempt Financial Adviser for the purposes of the Financial Advisers Act (Singapore Statute Cap.110). Registered Office: 1 Raffles Quay, #27-13 South Tower, Singapore 048583. In Australia, this material is being circulated by way of an arrangement with Aviva Investors Pacific Pty Ltd (AIPPL) for distribution to wholesale investors only. Please note that AIPPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIPPL in respect of any matters arising from, or in connection with, this material. AIPPL, a company incorporated under the laws of Australia with Australian Business No. 87 153 200 278 and Australian Company No. 153 200 278, holds an Australian Financial Services License (AFSL 411458) issued by the Australian Securities and Investments Commission. Business Address: Level 30, Collins Place, 35 Collins Street, Melbourne, Vic 3000, Australia.

The name “Aviva Investors” as used in this material refers to the global organization of affiliated asset management businesses operating under the Aviva Investors name. Each Aviva investors’ affiliate is a subsidiary of Aviva plc, a publicly- traded multi-national financial services company headquartered in the United Kingdom. Aviva Investors Canada, Inc. (“AIC”) is located in Toronto and is registered with the Ontario Securities Commission (“OSC”) as a Portfolio Manager, an Exempt Market Dealer, and a Commodity Trading Manager. Aviva Investors Americas LLC is a federally registered investment advisor with the U.S. Securities and Exchange Commission. Aviva Investors Americas is also a commodity trading advisor (“CTA”) registered with the Commodity Futures Trading Commission (“CFTC”) and is a member of the National Futures Association (“NFA”). AIA’s Form ADV Part 2A, which provides background information about the firm and its business practices, is available upon written request to: Compliance Department, 225 West Wacker Drive, Suite 2250, Chicago, IL 60606.

Related views